
Sika Interplant Systems Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
Sika Interplant Systems CMP Rs.1,132. Q1 FY27E revenue Rs.56-65 Cr. PAT estimate Rs.9-11 Cr. 12-month target Rs.923-1,071.
Updated: 7 Jul 2026 • 3:55 pm
Posted by:

Sika Interplant Systems Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Sika Interplant Systems shares trading at Rs.1,132 against a market capitalisation of Rs.2,489 Cr and a price-to-earnings multiple of 68.3. As an industrials and capital goods name on the NSE and BSE, Sika Interplant Systems enters the Sika Interplant Systems Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
This Sika Interplant Systems Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.70 Cr revenue and Rs.10 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.
Get Free Investment Predictions and Sika Interplant Systems Research at Univest
About Sika Interplant Systems
Sika Interplant Systems (NSE: SIKA) operates in the industrials and capital goods space and is tracked on Univest under its NSE and BSE listings. Ahead of the Sika Interplant Systems Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.42 Cr and net profit of Rs.8 Cr, forming the base against which the Sika Interplant Systems Q1 Results FY27 estimates in this article are built. This Sika Interplant Systems Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.
Sika Interplant Systems Q1 FY27 Estimates
| Metric | Q1 FY27E (Range) | Q1 FY26 Actual | YoY Growth |
|---|---|---|---|
| Revenue (Rs. Cr) | 56-65 | 70 | -13.4% |
| Net Profit / PAT (Rs. Cr) | 9-11 | 10 | -1.0% |
| Results Date | July-August 2026 (indicative) | ||
| 12-Month Target (Uniresearch Estimate) | Rs.923-1,071 | ||
Key Catalysts to Watch
1. Order Book Execution
Healthy order book execution translating into revenue recognition for the quarter is one of the primary variables that analysts are tracking ahead of Sika Interplant Systems’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Sika Interplant Systems share price target or faces renewed pressure.
2. Capex Revival in User Industries
Capex revival in core user industries supporting fresh order inflows is one of the primary variables that analysts are tracking ahead of Sika Interplant Systems’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Sika Interplant Systems share price target or faces renewed pressure.
3. Operating Leverage
Operating leverage on higher volumes aiding margin expansion versus last year is one of the primary variables that analysts are tracking ahead of Sika Interplant Systems’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Sika Interplant Systems share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Sika Interplant Systems’s live price and Q1 FY27 result updates.
Key Risks to the Sika Interplant Systems Q1 Results FY27 Outlook
- Order execution delays pushing revenue recognition to later quarters.
- Raw material and input cost inflation pressuring margins.
- Slower capex recovery in key end-user industries affecting order inflows.
Q4 FY26 Performance Context for the Sika Interplant Systems Q1 Results FY27 Print
Sika Interplant Systems closed Q4 FY26 with revenue of Rs.42 Cr and net profit of Rs.8 Cr, a year-on-year revenue change of -13.4% and PAT change of -1.0% versus Q4 FY25. This base underpins the Sika Interplant Systems Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Sika Interplant Systems Q1 Results FY27 commentary once reported.
Technical Analysis Ahead of Sika Interplant Systems Q1 Results FY27
Sika Interplant Systems shares last traded at Rs.1,132. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Sika Interplant Systems Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Sika Interplant Systems Q1 Results FY27 trailing-growth framework points to a range of Rs.1,034-1,124 for Sika Interplant Systems, contingent on the Sika Interplant Systems Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Sika Interplant Systems Q1 Results FY27 view for Sika Interplant Systems works out to Rs.923-1,071, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a cautious bias is how Univest research categorises the stock heading into Sika Interplant Systems Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Sika Interplant Systems Q1 Results FY27 analysis would put Sika Interplant Systems in a Rs.855-1,059 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.
What to Watch in the Sika Interplant Systems Q1 Results FY27 Print
- Revenue and PAT versus the Sika Interplant Systems Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Sika Interplant Systems Q1 Results FY27 narrative.
- Healthy order book execution translating into revenue recognition for the quarter
- Order execution delays pushing revenue recognition to later quarters
Conclusion on Sika Interplant Systems Q1 Results FY27
Sika Interplant Systems enters the Q1 FY27 results season trading at Rs.1,132, with the 12-month Uniresearch target range of Rs.923-1,071 reflecting a tracking with a cautious bias stance. Investors tracking the Sika Interplant Systems Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Sika Interplant Systems Q1 Results FY27
When are Sika Interplant Systems Q1 FY27 results expected?
Ans. Sika Interplant Systems’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Sika Interplant Systems Q1 FY27 revenue estimate?
Ans. The Uniresearch trailing-growth estimate for Sika Interplant Systems’s Q1 FY27 revenue is Rs.56-65 Cr, based on the Q1 FY26 base of Rs.70 Cr.
What is the Sika Interplant Systems share price target?
Ans. The 12-month Uniresearch estimate for Sika Interplant Systems share price target is Rs.923-1,071, based on trailing growth and current valuation multiples.
Is Sika Interplant Systems a good buy before Q1 FY27 results?
Ans. Sika Interplant Systems is tracking with a cautious bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Sika Interplant Systems’s Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and healthy order book execution translating into revenue recognition for the quarter.
Where can I track Sika Interplant Systems share price live?
Ans. Sika Interplant Systems share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
Recent Articles

Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
22 July 2026

Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
21 July 2026

Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
21 July 2026

Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
21 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series VI: NAV, Returns and Maturity Status Compared
Popular this week
Intraday Stocks for Today: UltraTech Cement, ICICI Bank and HDFC Bank, Analyst Top Picks for 22 July 2026
Sundaram Long Term Tax Advantage Fund Series IV vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series II vs SBI Series IV: NAV, Returns and Maturity Status Compared
Sundaram Long Term Tax Advantage Fund Series III vs UTI Series VI: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





